BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27487134)

  • 1. Overcoming chemoresistance in prostate cancer with Chinese medicine Tripterygium wilfordii via multiple mechanisms.
    Wang Z; Ravula R; Shi L; Song Y; Yeung S; Liu M; Lau B; Hao J; Wang J; Lam CW; Chow MS; Huang Y
    Oncotarget; 2016 Sep; 7(38):61246-61261. PubMed ID: 27487134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
    Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J
    Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells.
    Natsagdorj A; Izumi K; Hiratsuka K; Machioka K; Iwamoto H; Naito R; Makino T; Kadomoto S; Shigehara K; Kadono Y; Lin WJ; Maolake A; Mizokami A
    Cancer Sci; 2019 Jan; 110(1):279-288. PubMed ID: 30426599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posttranscriptional Regulation of Human Antigen R by miR-133b Enhances Docetaxel Cytotoxicity Through the Inhibition of ATP-Binding Cassette Subfamily G Member 2 in Prostate Cancer Cells.
    Liu H; Song X; Hou J; Zhao Z; Chang J
    DNA Cell Biol; 2018 Mar; 37(3):210-219. PubMed ID: 29327946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual responsive micelles capable of modulating miRNA-34a to combat taxane resistance in prostate cancer.
    Lin F; Wen D; Wang X; Mahato RI
    Biomaterials; 2019 Feb; 192():95-108. PubMed ID: 30447399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemosensitizing Effect and Efficacy of Wilforlide A in Combination With Docetaxel in Drug-resistant Prostate Cancer.
    Wang Z; Yeung S; Yang S; Huang Y; Sum Chow MS
    In Vivo; 2022; 36(5):2020-2031. PubMed ID: 36099129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro immunosuppressive and cytotoxic activities of Tripterygium wilfordii extract.
    He Y; Shi S; Zhang R; Shen W; Tu J; Ding Z; Fan Y
    Drug Chem Toxicol; 2015 Apr; 38(2):145-51. PubMed ID: 24845166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells.
    Souchek JJ; Davis AL; Hill TK; Holmes MB; Qi B; Singh PK; Kridel SJ; Mohs AM
    Mol Cancer Ther; 2017 Sep; 16(9):1819-1830. PubMed ID: 28615298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo.
    Yan J; Wang Y; Zhang X; Liu S; Tian C; Wang H
    Drug Deliv; 2016 Jun; 23(5):1757-62. PubMed ID: 26203689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.
    Singh S; Chitkara D; Mehrazin R; Behrman SW; Wake RW; Mahato RI
    PLoS One; 2012; 7(6):e40021. PubMed ID: 22768203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147.
    Hao J; Madigan MC; Khatri A; Power CA; Hung TT; Beretov J; Chang L; Xiao W; Cozzi PJ; Graham PH; Kearsley JH; Li Y
    PLoS One; 2012; 7(8):e40716. PubMed ID: 22870202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compatibility with Panax notoginseng and Rehmannia glutinosa Alleviates the Hepatotoxicity and Nephrotoxicity of Tripterygium wilfordii via Modulating the Pharmacokinetics of Triptolide.
    Zhang Q; Li Y; Liu M; Duan J; Zhou X; Zhu H
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29351251
    [No Abstract]   [Full Text] [Related]  

  • 13. Bone Microenvironment Changes in Latexin Expression Promote Chemoresistance.
    Zhang M; Osisami M; Dai J; Keller JM; Escara-Wilke J; Mizokami A; Keller ET
    Mol Cancer Res; 2017 Apr; 15(4):457-466. PubMed ID: 28087740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of CKBM on prostate cancer cell growth in vitro and in vivo.
    Liu ES; Luk SC; Leung ET; Lee WH; Yuen WF; Kwok KM; Siu SW; Kwok NS; Xing HT; Wu M; Pang SF
    J Chemother; 2008 Apr; 20(2):246-52. PubMed ID: 18467253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic window analysis of Tripterygium wilfordii processed by liquorice: an instantiation using allergic contact dermatitis].
    Yu XH; Dong JM; Wu H; Wang JB; Ma ZJ; Zhang CE
    Zhongguo Zhong Yao Za Zhi; 2019 Aug; 44(16):3454-3459. PubMed ID: 31602909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of the active components in Tripterygium wilfordii leading to its acute hepatotoxicty and nephrotoxicity.
    Li XX; Du FY; Liu HX; Ji JB; Xing J
    J Ethnopharmacol; 2015 Mar; 162():238-43. PubMed ID: 25582490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased involvement of Panax notoginseng in the mechanism of decreased hepatotoxicity induced by Tripterygium wilfordii in rats.
    Zhang B; Zhang Q; Liu M; Zhang X; Shi D; Guo L; Duan J; Zhu H; Zhou X
    J Ethnopharmacol; 2016 Jun; 185():243-54. PubMed ID: 26997552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Micellar Delivery of miR-34a Modulator Rubone and Paclitaxel in Resistant Prostate Cancer.
    Wen D; Peng Y; Lin F; Singh RK; Mahato RI
    Cancer Res; 2017 Jun; 77(12):3244-3254. PubMed ID: 28428276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymeric Micellar Delivery of Novel Microtubule Destabilizer and Hedgehog Signaling Inhibitor for Treating Chemoresistant Prostate Cancer.
    Yang R; Chen H; Guo D; Dong Y; Miller DD; Li W; Mahato RI
    J Pharmacol Exp Ther; 2019 Sep; 370(3):864-875. PubMed ID: 30996033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer.
    Garrido MF; Martin NJ; Bertrand M; Gaudin C; Commo F; El Kalaany N; Al Nakouzi N; Fazli L; Del Nery E; Camonis J; Perez F; Lerondel S; Le Pape A; Compagno D; Gleave M; Loriot Y; Désaubry L; Vagner S; Fizazi K; Chauchereau A
    Clin Cancer Res; 2019 Jan; 25(2):710-723. PubMed ID: 30322877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.